Clinical Trials
7 trialsNCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02826161 2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03053297 2018-02-08
PANORAMA
AstraZeneca
Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated